Patients with the UGT1A1*28 or UGT1A1*6 polymorphism were reported to have reduced UGT1A1 enzyme activity, elevated SN-38 concentration, and increased risk for severe diarrhea or neutropenia following initiation of irinotecan treatment [3]. This evidence concerns the gene UGT1A1 and neutropenia.